Open Payments Expansion Act

This bill requires pharmaceutical companies and group purchasing organizations to publicly disclose payments made to patient advocacy groups. Starting March 31, 2027, and annually after, these entities must report the name of the organization and the payment amount to the government. The disclosure covers both direct payments and indirect payments routed through third parties. It directly affects patient advocacy groups that provide education, support, or advocacy for patients with medical conditions, as defined by the bill. The requirement applies to organizations meeting specific IRS 501(c)(3) criteria focused on patient care.